Read as PDF
Lund, Sweden, 17th of October 2017 – Xintela AB (publ)
announces that Keld Søndergaard has resigned from the company’s Board of
Directors, citing personal reasons. Xintela’s larger shareholders, acting as an
informal nomination committee, will consider potential replacement candidates
to propose to the next Annual General Meeting.
Keld Søndergaard was
elected as a new member of the Board at the Annual General Meeting on the 18th
of May 2017. The Board regrets the loss of Keld as a member, but feels certain a
suitable replacement will be found.
Shareholders who have
suggestions for appropriate candidates may contact the Chairman, Greg
Batcheller, via the CEO Evy Lundgren-Åkerlund.
The Xintela Board wishes
Keld Søndergaard all the best in his future endeavors.
Xintela AB (publ)
Evy
Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se
About Xintela
Xintela develops medical products for regenerative
medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and
assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses,
the company has shown that stem cells are safe to use and that they have a positive effect on the articular
cartilage and the underlying bone after an injury. XINMARK® is also used for the development of an antibody- based
treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common
and aggressive form of brain tumors in adults. Positive preclinical results
from cell studies and animal model have shown that the antibody
has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq
First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB,
+46 8-463 80 00.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 17th of October 2017, at 09.00 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Chairman Gregory Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Investor Meeting on March 16, 2023.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Fall Summit 2022 on November 30.
CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
BioStock interview with Xintela's CMO and board member Sven Kili.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.